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 CAPSULE
Postmenopausal  women  with  PCOS  have  increased  cerebro-vascular  events  and 
cardiovascular morbidity. Our best long-term strategy is information, acknowledging women 
with PCOS of their risk for metabolic and cardiovascular diseases.
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 ABSTRACT
Most available data suggest that the prevalence of cardiovascular diseases in women 
with polycystic ovary syndrome (PCOS) is smaller than what expected on the basis of the risk 
calculation  during  fertile  age;  therefore,  we  need  many  more  studies  on  their  long  term 
cardiovascular consequences although evidence is accumulating that women with PCOS at 
postmenopausal  age  have  an  increase  in  cerebro-vascular  events  and  in  cardiovascular 
morbidity.  These  events  are  partially  related  to  the  persisting  hyperandrogenism  but  are 
mostly correlated to the excessive body weight (mainly to the visceral obesity); this suggests 
that our best long term strategy is the information, acknowledging women with PCOS of their 
high risk for metabolic and cardiovascular diseases.
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 Introduction
Fertile women with polycystic ovary syndrome (PCOS) have increased cardiovascular 
risk and this  finding has been consistently confirmed across several  geographic areas and 
ethnic  groups  (1).  Yet,  the  risk  for  cardiovascular  diseases  in  women  with  PCOS  at 
postmenopausal age is largely unknown. Women with PCOS are more likely than normally 
cycling women to have insulin resistance, central adiposity,  dyslipidemia and hypertension 
(2). 
On the basis of such elevated prevalence of metabolic and cardiovascular risk factors, 
a clear and significant increase in cardiovascular outcome was expected in postmenopausal 
age. However, there is still not clear evidence for this and, although new studies are showing 
increased  cardiovascular  morbidity  (see  below),  most  available  data  suggest  that  the 
prevalence of cardiovascular diseases in women with PCOS is smaller than what expected on 
the basis of the risk calculation during fertile age (3). 
Markers of cardiovascular risk in PCOS
Several markers of cardiovascular risk have been found to be altered in PCOS. Serum 
markers include C-reactive protein (4-6), adiponectin (7,8), plasminogen activator-1 (9), Von 
Willebrand factor (10), endothelin-1 (11), homocysteine (12) and markers of oxidative stress 
(13) and the majority of the studies have demonstrated that such abnormalities were related to 
insulin  resistance  and  obesity  in  women  with  PCOS  (14).  Further,  dyslipidemia  is  very 
common  and  may  represent  the  most  common  metabolic  abnormality  in  PCOS,  with  a 
prevalence of up to 70% according to the National Cholesterol Education Program criteria 
(14,15). Dyslipidemia usually include low HDL-cholesterol levels and elevated triglyceride 
concentrations while increased LDL and total cholesterol have been also found but with a 
lower prevalence (14). Beyond plasma lipids, women with PCOS have lower LDL size due to 
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 increased levels of atherogenic small, dense LDL [16-18] and recent studies have suggested 
the “quality” and not only the “quantity” of LDL is strongly associated with cardiovascular 
risk (19).
Other  studies  have  evaluated  the  relationships  between  PCOS  and  cardiovascular 
diseases using markers of subclinical atherosclerosis. These studies focused on the arterial 
wall and the myocardium and included functional studies (i.e. those investigating ventricular 
function,  arterial  stiffness  and  endothelial  function)  and morphological  studies  (i.e.  those 
investigating arterial thickness and calcification) (14). Echocardiographic studies have shown 
increased  early  left  ventricular  diastolic  dysfunction  and lower ejection  fraction  in  PCOS 
(20,21). Other studies demonstrated increased pulse wave velocity of the brachial artery and 
increased stiffness of both internal and external carotid arteries (22,23). Alterations in both 
endothelium-dependent  and  independent  vasodilator  responses  of  the  brachial  artery  in 
women with PCOS have been also reported (24-28).  Further,  morphological  studies  have 
shown that  women with PCOS have  increased  carotid  intima  media  thickness  as  well  as 
higher  incidence  of  coronary  and  aortic  arterial  calcification  (29-32).  These  reports  are 
complemented with angiographic data in women showing an association between coronary 
artery disease and polycystic ovaries (33).
Changes in polycystic ovaries and androgens with age
Several studies have shown that androgen secretion spontaneously decreases after the 
age  of  35  in  normal  and  PCOS  women  (34,35)  and  that  in  the  general  population  the 
prevalence of polycystic ovaries appears to decrease with age too (36). Further, women with 
polycystic ovaries may regain normal menses with age (37) and may also get spontaneous 
fertility  (38).  Therefore,  the  diagnosis  of  PCOS becomes  less  common with  age  and the 
syndrome shows lower alterations, including reduced androgen levels.
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 The decrease of circulating androgens in women with PCOS during their late fertile 
age may play a role in the reduction of their cardiovascular risk. Interestingly,  in a recent 
study that  demonstrated  an increased  number  of  cardiovascular  events  in  postmenopausal 
women with PCOS, a significant association was found between postmenopausal androgen 
levels and cardiovascular events (39). Therefore, androgens may play an important role on 
cardiovascular outcome and the development of vascular events may be influenced by the 
presence of androgen excess after menopause.   
Body weight and diabetes in post-menopausal age 
Early reports have suggested that women with PCOS may develop menopause at a 
later age than control women (40). Yet, more recent studies have shown that menopausal age 
is similar in women with or without PCOS (39). It has been reported that, at least in the USA, 
there is a greater morbidity of surgical menopause due to bilateral oopherectomy in women 
with  clinical  features  of  PCOS (39).  Although there  is  still  no clear  explanation  for  this 
(uterine problems such as endometrial hyperplasia or fibromas ?), menopause at young age 
may play a role for the future life of these women (e.g., earlier appearance of cardiovascular 
disease, bone loss).
  Further,  it  has been shown that postmenopausal  women with PCOS have higher 
prevalence  of  obesity  and  type-2  diabetes  than  postmenopausal  controls  (39,40).  Both 
disorders may contribute to the increase of cerebro-vascular and cardio-vascular events in this 
category of subjects (39). As previously reported, the increase of circulating inflammatory 
factors significantly influence the cardiovascular outcome in postmenopausal PCOS (39) and 
it is has been shown that this is linked to the role of the visceral adipose tissue (41). These 
findings  suggest  that  body  weight  should  be  one  of  the  main  targets  of  the  long-term 
treatment of PCOS (42).
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 Cardiovascular risk in post-menopausal age
Main studies on cardiovascular  outcome in women with PCOS are summarized  in 
Table 1. With the term “cardiovascular” we refer to a generalized vascular disease which 
affects also the heart and not simply to atherosclerotic changes affecting the cardiac muscle. 
Initial studies on the prevalence of cardiovascular diseases in postmenopausal women, who 
were probably  affected  by PCOS during their  fertile  age,  indicated  an  increased  risk  for 
developing  myocardial  infarction  (3).  It  was  calculated  that  women  with PCOS have 7.1 
higher  risk  to  develop  myocardial  infarction  than  non-PCOS women  (41).  However,  the 
number of the studied subjects was rather small (only 33 patients) and the authors did not 
found an increased cardiovascular morbidity but only an increased risk (41). 
A  later  and  larger  study  (786  postmenopusal  women)  did  not  demonstrate  any 
difference  in  cardiovascular  morbidity  and mortality  between women with PCOS and the 
general population (42). On the basis of the observed alterations in several markers of clinical 
and subclinical  atherosclerosis,  these results  were somehow unexpected and suggested the 
absence of long term cardiovascular consequences of PCOS. However, this study has been 
criticized because the diagnosis of PCOS was based on historical data during a very large 
period (hospital records between 1930 and 1979) and was not supported by hormonal studies 
or ovarian morphology. 
In a successive report, the same authors (43) studied a more restricted but carefully 
selected cohort of patients (309 postmenopausal women who were diagnosed as affected by 
PCOS before 1979 in the United Kingdom). The authors didn’t show any increase in coronary 
heart disease (odd ratio 1.5) but found higher prevalence of cerebrovascular outcome (odd 
ratio 2.8). Interestingly,  in the Framingham study the reported presence of oligomenorrhea 
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 during  fertile  years  wasn’t  associated  to  cardiac  events  but  to  increased  number  of 
cerebrovascular events (44). 
A recent study has shown that women with PCOS have increased prevalence of some 
cardiac events. In fact, studying a large group of postmenopausal women who underwent an 
angiographic study because of the suspect of myocardial  ischemia,  an adverse association 
between clinical  and hormonal  features  of PCOS and cardiovascular  outcome in a 6-year 
follow-up has been recently demonstrated (39). While other studies are needed to confirm and 
expand this study, it is clear that PCOS is associated to an increased risk for cerebrovascular 
events (stroke) and probably also for fatal and nonfatal coronary heart disease. In addition, 
this  risk is  more severe in patients  having higher androgens but mostly presenting higher 
inflammatory factors in the blood. These findings are somewhat similar to those found  in a 
cross-sectional  study  on  old  non-diabetic  postmenopausal  women  where  atherosclerotic 
cardiovascular events were associated with features of a putative PCOS phenotype (45). 
Conclusions
We need many more studies on long term consequences of PCOS. The data are few 
and often conflicting. However, there is increasing evidence that postmenopausal women with 
PCOS have more cerebro-vascular events and probably cardiovascular morbidity too. This 
may be partially related to the persisting hyperandrogenism but is mostly related to the altered 
body  weight  (usually  due  to  the  visceral  obesity).  Therefore,  one  of  the  best  long-term 
strategies is information, acknowledging women with PCOS of their high risk for metabolic 
and cardiovascular diseases.
9
 REFERENCES
1) Guzick DS. Cardiovascular risk in PCOS. J Clin Endocrinol Metab. 2004; 89:3694-5.  
2) Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann 
Intern Med. 2000; 132:989-93.
3) Legro  RS.  Polycystic  ovary  syndrome  and  cardiovascular  disease:  a  premature 
association? Endocr Rev 2003; 24:302-12. 
4) Kelly  CC,  Lyall  H,  Petrie  JR,  Gould GW, Connell  JM, Sattar  N.  Low grade chronic 
inflammation  in  women  with  polycystic  ovarian  syndrome.  J  Clin  Endocrinol  Metab 
2001;86:2453–5.
5) Boulman N, Boulman N, Levy Y, Leiba R, Shachar S, Linn R et al. Increased C-reactive 
protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin 
Endocrinol Metab 2004;89:2160–5.
6) Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T et al. The polycystic 
ovary  syndrome  per  se  is  not  associated  with  increased  chronic  inflammation.  Eur  J 
Endocrinol 2004;150:525–32.
7) Panidis  D,  Kourtis  A,  Farmakiotis  D,  Mouslech  T,  Rousso  D,  Koliakos  G.  Serum 
adiponectin  levels  in  women  with  polycystic  ovary  syndrome.  Hum  Reprod 
2003;18:1790–6.
8) Spranger J, Möhlig M, Wegewitz U, Ristow M, Pfeiffer AF, Schill T et al. Adiponectin is 
independently  associated  with  insulin  sensitivity  in  women  with  polycystic  ovary 
syndrome. Clin Endocrinol 2004;61:738–46.
9) Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles 
and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the 
polycystic ovary syndrome. Clin Endocrinol 1996;45:623–9.
10
 10) Dahlgren E, Janson PO, Johansson S, Lapidus L, Lindstedt G, Tengborn L.  Hemostatic 
and  metabolic  variables  in  women  with  polycystic  ovary  syndrome.  Fertil  Steril 
1994;61:455–60.
11) Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in 
women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J 
Clin Endocrinol Metab 2001;86:4666–73.
12) Loverro  G,  Lorusso  F,  Mei  L,  Depalo  R,  Cormio  G,  Selvaggi  L.  The  plasma 
homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 
2002;53:157–62.
13) Sabuncu T, Vural H, Harma M. Oxidative stress in polycystic  ovary syndrome and its 
contribution to the risk of cardiovascular disease. Clin Biochem 2001;34:407–13.
14) Cussons  AJ,  Stuckey  BG,  Watts  GF.  Cardiovascular  disease  in  the  polycystic  ovary 
syndrome: new insights and perspectives. Atherosclerosis 2006; 185:227-39 
15) Legro  RS,  Kunselman  AR,  Dunaif  A.  Prevalence  and  predictors  of  dyslipidemia  in 
women with polycystic ovary syndrome. Am J Med 2001;111:607–13.
16) Berneis  K,  Rizzo  M,  Fruzzetti  F,  Lazzaroni  V,  Carmina  E.  Atherogenic  lipoprotein 
phenotype and LDL size and subclasses in women with polycystic ovary syndrome. J Clin 
Endocrinol Metab 2007; 92:186-189.
17) Valkenburg  O,  Steegers-Theunissen  RP,  Smedts  HP,  Dallinga-Thie  GM,  Fauser  BC, 
Westerveld EH et al. A more atherogenic serum lipoprotein profile is present in women 
with polycystic  ovary syndrome:  a case-control  study.  J Clin  Endocrinol  Metab 2008; 
93:470-6.
18) Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinas GA, Carmina E. 
Atherogenic forms of dyslipidemia in women with polycystic ovary syndrome. Int J Clin 
Pract In press
11
 19) Rizzo M, Berneis  K. Low-density-lipoproteins  size and cardiovascular  risk assessment 
QJM – Int J Med 2006. 99: 1-14.
20) Tíras MB, Yalcìn R, Noyan V, Maral I, Yìldìrìm M, Dörtlemez O et al.  Alterations in 
cardiac  flow  parameters  in  patients  with  polycystic  ovarian  syndrome.  Hum  Reprod 
1999;14:1949–52.
21) Orio  F,  Palomba  S,  Spinellli  L,  Cascella  T,  Tauchmanova  L,  Zullo  F  et  al.  The 
cardiovascular risk of young women with polycystic ovary syndrome: an observational, 
analytical, prospective case-control study. J Clin Endocrinol Metab 2004; 89:3696–3701
22) Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM. Altered vascular function 
in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:742–
6.
23) Lakhani K, Constantinovici N, Purcell WM, Fernando R, Hardiman P. Internal carotid 
artery haemodynamics in women with polycystic ovaries. Clin Sci (Lond) 2000;98:661–5.
24) Tarkun I, Arslan BC, Cantürk Z, Türemen E, Sahin T, Duman C. Endothelial dysfunction 
in young women with polycystic ovary syndrome: relationship with insulin resistance and 
low-grade chronic inflammation. J Clin Endocrinol Metab 2004;89:5592–6.
25) Orio  F  Jr,  Palomba  S,  Cascella  T,  De  Simone  B,  Di  Biase  S,  Russo  T et  al.  Early 
impairment  of endothelial  structure and function in young normal-weight women with 
polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:4588–93.
26) Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A et 
al.  Predictors  of  endothelial  dysfunction  in  young  women  with  polycystic  ovary 
syndrome. J Clin Endocrinol Metab 2005;90:5088–95.
27) Diamanti-Kandarakis  E,  Alexandraki  K,  Protogerou  A,  Piperi  C,  Papamichael  C, 
Aessopos A et al. Metformin administration improves endothelial function in women with 
polycystic ovary syndrome. Eur J Endocrinol 2005;152:749–56.
12
 28) Carmina  E,  Orio  F,  Palomba  S,  Longo  RA,  Cascella  T,  Colao  A,  et  al.  Endothelial 
dysfunction  in  PCOS:  role  of  obesity  and  adipose  hormones.  Am  J  Med. 
2006;119(4):356.e1-6. 
29) Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu K, Zborowski J, Remsberg K et 
al. Evidence for association between polycystic ovary syndrome and premature carotid 
atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;  20:2414–
2421.
30) Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr. Carotid 
atherosclerosis  in  women with polycystic  ovary syndrome:  initial  results  from a case-
control study. Am J Obstet Gynecol 1996;174:1224–9.
31) Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. 
Evidence for an association between metabolic cardiovascular syndrome and coronary and 
aortic  calcification  among women with polycystic  ovary syndrome.  J  Clin  Endocrinol 
Metab 2004;89:5454–61.
32) Christian  RC,  Dumesic  DA,  Behrenbeck  T,  Oberg  A,  Sheedy  PF,  Fitzpatrick  L. 
Prevalence and predictors of coronary artery calcification in women with polycystic ovary 
syndrome. J Clin Endocrinol Metab 2003; 88:2562–2568.
33) Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent 
of  coronary  artery  disease  in  women  having  cardiac  catheterization.  Ann  Intern  Med 
1997;126:32–5.
34) Labrie  F,  Belanger  A,  Cusan  L,  Gomez  J,  Candas  B.  Marked  decline  in  serum 
concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites 
during aging. J Clin Endocrinol Metab  1997; 82: 2396-2402
13
 35) Bili H, Laven J, Imani B, Eijkemans MJ, Fauser BC. Age-related differences in features 
associated with polycystic  ovary syndrome in normogonadotrophic oligo-amenhorroeic 
infertile women of reproductive years. Eur J Endocrinol 2001; 145: 749-55
36) Koivunen R, Laatikainen T, Tomas C, Huhtaniemi I, Tapanainen J, Martikainen H. The 
prevalence  of  polycystic  ovaries  in  healthy  women.  Acta  Obstet  Gynecol  Scand 
1999;78:137-41.
37) Elting  MW, Korsen TJ,  Rekers-Mombarg  LT,  Schoemaker  J.  Women with polycystic 
ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod. 2000; 15:24-8
38) Vulpoi C, Lecomte C, Guilloteau D, L Lecomte  P.  Ageing  and  reproduction:  is 
polycystic ovary syndrome an exception? Ann. Endocrinol (Paris) 2007; 68:45-50 
39) Shaw  LJ,  Merz  CN,  Azziz  R,  Stanczyk  FZ,  Sopko  G,  Braunstein  GD  et  al.  Post-
Menopausal  Women  with  a  History  of  Irregular  Menses  and  Elevated  Androgen 
Measurements at High Risk for Worsening Cardiovascular Event-Free Survival: Results 
from the National Institutes of Health National Heart, Lung, and Blood Institute (NHLBI) 
Sponsored Women's Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab. 
2008 Jan 8; [Epub ahead of print] 
40) Dahlgren E, Johansson S, Lindstet G, Knutsson F, Oden A, Janson PO et al. Women with 
Polycystic  Ovary  Syndrome  wedge  resected  in  1956-1965:  a  long-term  follow-up 
focusing on natural history and circulating hormones. Fertil Steril 1992; 57: 505-13 
41) Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and 
risk for myocardial infarction. Evaluated from a risk factor model based on a prospective 
population study of women. Acta Obstet Gynecol Scand 1992; 71:599–604.
42) Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS.. Mortality of woman with 
polycystic ovary syndrome at long term follow up. J Clin Epidemiol 1998;51:581-86. 
14
 43) Wild SH, Pierpoint T, Mckeigue PM, Jacobs HS. Cardiovascular disease in women with 
polycystic  ovary  syndrome  at  long-term follow-up:  a  retrospective  cohort  study.  Clin 
Endocrinol 2000;52:595-600.
44) Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the 
Framingham Study. Am J Public Health 1951; 41:279-81
45) Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-
insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in 
perimenopausal  women  with  a  history  of  the  polycystic  ovary  syndrome.  2000  Hum 
Reprod 15:785–789.
15
Table 1. 
Long-term studies examining the prevalence of cardiovascular diseases in women with PCOS.
Authors 
(year)
Study design n. of  
PCOS
Mean age,
years
PCOS definition Results Cardiovascular end points
Dahlgren 
(1992)
population study 33 50 (40-59) Histopathology  typical  of  PCOS  at 
wedge resection
Positive increased  risk  (relative  risk  of  7.4)  of 
developing myocardial infarction in PCOS 
compared to age-matched women
Pierpoint 
(1998)
population study 786 >45 at the time 
of follow-up
Histological evidence of PCOS or 
macroscopic evidence of ovarian 
dysfunction or clinical diagnosis
Negative no difference in cardiovascular deaths 
between PCOS rates and national rates in a 
mean follow-up period of 30 years
Wild
(2000)
population study 678 <75 at the time 
of follow-up
Histological evidence of PCOS or 
macroscopic evidence of ovarian 
dysfunction or clinical diagnosis
Negative no difference in cardiovascular morbidity 
and mortality compared to age-matched 
women
Cibula
(2000)
Cross-sectional 28 52±5 Wedge ovarian resection for typical 
clinical and morphologican 
symptoms of PCOS
Positive Increased coronary artery diseases in PCOS 
in relation to age- and BMI-matched 
women
Elting
(2001)
population study 346 39 (30-56) oligo- or amenorrhoea and increased 
LH with normal FSH 
Negative no difference in cardiac events in relation to 
age-matched women
Talbott 
(2004)
prospective 127 35±8 History of chronic anovulation and 
hirsutism 
Positive increased  risk  (relative  risk  of  5.9)  of 
developing cardiovascular events in PCOS 
compared to age-matched women
Krentz 
(2007)
Cross-sectional 64 78±8 irregular menses, hyperandrogenism, 
infertility, central obesity, insulin 
resistance
Positive association between PCOS and 
cardiovascular diseases in non-diabetic 
post-menopausal women
Shaw 
(2008)
Prospective, 
multi-center
104 63±10 premenopausal history of irregular 
menses and current biochemical
evidence of hyperandrogenemia.
Positive association between clinical features of 
PCOS and cardiovascular outcomes in a 5-
year follow-up
